Abstract
New and Improved Antipsychotic Drugs Find Increased Use in Bipolar
Disorder Market
The success of innovative atypical antipsychotic drugs such as Zyprexa,
Risperdal, and Seroquel has turned the focus of drug manufacturers from the
schizophrenia market to the bipolar disorder market. Not only do these new drugs
effectively control the manic symptoms of the illness but they also offer a
superior side effects profile by eliminating related complications such as
movement disorders and prolactin elevation. Another advantage is that these
newer drugs demand considerably less treatment time than older medications. For
instance, Zyprexa takes an average of about 172 days as opposed to the 470 days
taken during lithium therapy. The FDA’s approval of these drugs is expected to
further fuel revenue.
This Frost & Sullivan research service evaluates the current and future
prospects for atypical medications in the U.S. antipsychotic market in areas
such as schizophrenia, bipolar disorder, various elderly dementias, psychotic
and treatment-resistant depression, and a series of anxiety disorders. It
analyzes the challenges and driving factors that are likely to assist drug
manufacturers in formulating their future marketing strategies. Additionally, it
provides disease overviews, pipeline product analysis, and market forecasts for
each of these segments.
Fiscal Pressures Exclude Zyprexa from the "Preferred Drug" List
of Several States
Even while newer antipsychotic treatments have provided millions of patients
with a new lease on life, the relatively high costs have curbed their uptake.
Moreover, the extra expenses involved have put many states under pressure to
reconsider paying for these drugs in their federal-state Medicaid programs.
Therefore states such as Kentucky, West Virginia, Florida, Maine, Oregon, and
Texas have taken Zyprexa off their "preferred drug" list.
"Since it accounts for the single largest portion of the overall drug
budget and costs double the price of Risperdal or Seroquel, Zyprexa seems to be
the favorite target of Medicaid’s cost cutting measures," points out the
analyst. To this end, Medicaid directors have initiated a ‘fail first’
policy, whereby only patients who have failed on less expensive antipsychotics
are allowed a trial of Zyprexa.
Abilify’s Success Likely to Negatively Impact Zyprexa
The emergence of Abilify in the atypical antipsychotics market is expected to
change market dynamics and further challenge Zyprexa’s role as market leader.
Zyprexa’s sales figures show that while product sales in 2002 were $350
million more than in 2001, the subsequent year has shown a definite dip. 2003
product sales were only $100 million greater than that of 2002. Abilify, on the
other hand, is expected to reach $1 billion in U.S. sales by the end of 2005.
"Abilify’s edge over Zyprexa lies in its ability to provide efficient
results without adverse side effects such as weight gain," says the
analyst. This has, in fact, been a major bone of contention with Zyprexa’s
competitors that point out that weight problems carry the associated risk of
diabetes. However, in the long term, it is quite likely that end users will be
ready to endure weight gain for a significant improvement in quality of life.
Table of Contents
- EXECUTIVE SUMMARY
- INTRODUCTION
- Overview
- Scope and Segmentation
- Research Methodology
- Market Overview
- Disease Insights
- Schizophrenia
- Bipolar Disorder
- Other Uses of Antipsychotics
- TOTAL MARKET
- Overview
- Market Development and Evolution
- Challenge 1: Low Medication Compliance Limits Revenue Potential
- Challenge 2: High Misdiagnosis Rates of Bipolar Disorder Constrain Market Growth
- Challenge 3: Growing Difficulty in Securing Reimbursement Due to High Cost of Therapy Curbs Revenue Growth
- Challenge 4: Selective Long-term Use of Atypical Antipsychotics in Bipolar Disorder Hampers Revenue Expansion
- Market Dynamics
- Market Size and Growth
- Antipsychotic Drug Usage by Disease Category
- Payers and Prescribers
- Product Positioning
- Product and Pricing Analysis
- FDA-Approved Indications
- Efficacy in Treating Schizophrenia
- Side Effects Profile
- Dosing and Formulations
- Efficacy in Treating Bipolar Disorder
- Off-label Usage
- Pricing Considerations
- Corporate Factors
- Market Forecasts and Trends
- Market and Technology Trends
- Pipeline Analysis
- Market Drivers
- Market Restraints
- Revenue Forecasts
- Frost & Sullivan Awards
- Advanced Research and Development Program Award
- Product Innovation Award
- SCHIZOPHRENIA MARKET
- Segment Highlights
- Disease Overview
- Patient Profile
- Prevalence and Incidence
- Diagnosis and Treatment
- Market Dynamics
- Market Overview
- Product Market Shares
- Industry Challenges
- Factors Affecting Market Growth
- Market and Technology Trends
- Revenue Forecasts
- BIPOLAR DISORDER MARKET
- Segment Highlights
- Disease Overview
- Patient Profile
- Prevalence and Incidence
- Diagnosis and Treatment
- Market Dynamics
- Market Overview
- Product Market Shares
- Industry Challenges
- Factors Affecting Market Growth
- Market and Technology Trends
- Revenue Forecasts
- OTHER OFF-LABEL MARKETS
- Segment Highlights
- Disease Overview
- Introduction
- Dementias
- Depression
- Anxiety Disorders
- Market Dynamics
- Market Overview
- Industry Challenges
- Factors Affecting Market Growth
- Market and Technology Trends
- Revenue Forecasts
- APPENDIX
- Decision Support Databases
- Prevalence of Schizophrenia
- Schizophrenia Advocacy Groups
- Nursing Home Residents
- Psychiatrists
- Neurologists
医薬品
その他のカテゴリ
FAQ